Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Cited by 117 Publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )
Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )
Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )
J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUD3dFB{UUN3ME2wMlA3OSEQvF2=	NVLXV2lrW0GQR1XS
ALL-PO	NG\JfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;OTWM2OD1yLkC2N\|U2KM7:TR?=	NGj6UFBUSU6JRWK=
697	M3\2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMEm5O\|Yh\|ryP	MXzTRW5ITVJ?
NCI-H748	NGjYWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyyUlZKSzVyPUCuNVA{OzRizszN	NXj3N4Z{W0GQR1XS
NKM-1	M3TCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLwWm9nUUN3ME2wMlExQTF{IN88US=>	M3PienNCVkeHUh?=
ES1	NW\UdW1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrtPZd3UUN3ME2wMlEyOjV3IN88US=>	MWnTRW5ITVJ?
NCI-H1963	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMUG1O\|kh\|ryP	M1v3cnNCVkeHUh?=
NCI-H1417	NGW1[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33VZ2lEPTB;MD6xNlk4PCEQvF2=	NHXaOoNUSU6JRWK=
NEC8	NUiwVolRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7hSmVCUUN3ME2wMlE{PTJ5IN88US=>	MXLTRW5ITVJ?
CRO-AP2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\Wb2h[UUN3ME2wMlE3QDh7IN88US=>	MWjTRW5ITVJ?
A3-KAW	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjFWHhKSzVyPUCuNVc3OjdizszN	M2j2NHNCVkeHUh?=
SF539	M1T3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT5e2ZSUUN3ME2wMlE6PTl\|IN88US=>	NWTBUHhvW0GQR1XS
NOS-1	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMUm2NVkh\|ryP	M4POTHNCVkeHUh?=
NTERA-S-cl-D1	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2f3ZWlEPTB;MD6yNFEyOyEQvF2=	MmD4V2FPT0WU
COR-L88	M4X1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHv5OYVKSzVyPUCuNlI6PTlizszN	M3\KV3NCVkeHUh?=
EM-2	NYr1THo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHlXGxKSzVyPUCuNlQxPzlizszN	M3H4S3NCVkeHUh?=
KARPAS-45	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVmwemg4UUN3ME2wMlI4QDN\|IN88US=>	MUjTRW5ITVJ?
DSH1	MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHlTopKSzVyPUCuNlg4ODhizszN	MoHJV2FPT0WU
HT-144	NGLjU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojmTWM2OD1yLkOwNlU3KM7:TR?=	MVLTRW5ITVJ?
ATN-1	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwM{C1O\|Yh\|ryP	M1W5PHNCVkeHUh?=
HEL	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTETWM2OD1yLkOxN\|Q5KM7:TR?=	NWrDcGN2W0GQR1XS
NB12	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fyRmlEPTB;MD6zNVc2PiEQvF2=	NUPIZ5dWW0GQR1XS
LU-139	M3j0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwM{O1NUDPxE1?	NX;iXGM5W0GQR1XS
J-RT3-T3-5	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwM{O3NVYh\|ryP	M3jzRnNCVkeHUh?=
MOLT-13	NUnPRlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwM{O4NUDPxE1?	MnPOV2FPT0WU
SR	NE\4clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vNe2lEPTB;MD6zOFI3OSEQvF2=	MWHTRW5ITVJ?
CMK	NUTvNnF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLqUGNbUUN3ME2wMlM2PzJ5IN88US=>	NE\J[pVUSU6JRWK=
ES8	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIe4TFZKSzVyPUCuN\|YxOjJizszN	MXPTRW5ITVJ?
LB647-SCLC	NVvVN4J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nNNGlEPTB;MD6zOlc{KM7:TR?=	MWfTRW5ITVJ?
TE-8	NUO3WJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwM{[5N\|Uh\|ryP	Mn[zV2FPT0WU
BV-173	NGTYUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\1T5FxUUN3ME2wMlM4OTJzIN88US=>	MX\TRW5ITVJ?
DEL	M3PDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzZfY9xUUN3ME2wMlM4PDh5IN88US=>	MW\TRW5ITVJ?
ARH-77	NYfITnY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\FSFFKSzVyPUCuN\|gyQTNizszN	NE\UNGpUSU6JRWK=
NCCIT	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljWTWM2OD1yLkO4OlQ6KM7:TR?=	MWLTRW5ITVJ?
RPMI-8402	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHKxfXJKSzVyPUCuN\|g4ODFizszN	NVPZRmRpW0GQR1XS
MONO-MAC-6	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwM{i3O\|Yh\|ryP	M1e5NHNCVkeHUh?=
SK-MM-2	MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwM{m4Olgh\|ryP	MnHrV2FPT0WU
CHP-126	MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLHTWM2OD1yLkSwNlMyKM7:TR?=	MXrTRW5ITVJ?
A101D	NIHvV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwNECzJO69VQ>?	NWDNPIU6W0GQR1XS
SCH	NYHJWJo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDzTWM2OD1yLkSwN\|QzKM7:TR?=	MWrTRW5ITVJ?
NMC-G1	NHy1boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX1UHdKSzVyPUCuOFA{PjdizszN	MWfTRW5ITVJ?
NCI-H209	NFy5eolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfrWphlUUN3ME2wMlQxPjF\|IN88US=>	MorqV2FPT0WU
MOLT-16	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkm5TWM2OD1yLkSxNFE4KM7:TR?=	NWPkTmh5W0GQR1XS
RPMI-6666	NGTK[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwNEGxNkDPxE1?	M1r5W3NCVkeHUh?=
OPM-2	NYPGUmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vQWGlEPTB;MD60NVUyOyEQvF2=	Mke2V2FPT0WU
MRK-nu-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fReWlEPTB;MD60N\|E2OyEQvF2=	NUXGbnZTW0GQR1XS
BC-1	NFPvNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjJTZJKSzVyPUCuOFM1ODNizszN	MWrTRW5ITVJ?
MHH-NB-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwNEO0OVMh\|ryP	NFq5Z\|NUSU6JRWK=
Ramos-2G6-4C10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnO5TWM2OD1yLkSzPFk4KM7:TR?=	NVu0VWd3W0GQR1XS
LS-513	NXjScFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\3NY9KSzVyPUCuOFQ2ODFizszN	MlviV2FPT0WU
K5	NX6wVIM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzkV2ppUUN3ME2wMlQ4ODJ3IN88US=>	M1XBRnNCVkeHUh?=
HOP-62	M2DkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwNEizOVgh\|ryP	Mkf5V2FPT0WU
NCI-H187	NFvHTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwNEmyNlch\|ryP	NXG5WHk4W0GQR1XS
BE-13	NFXBUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDCTWM2OD1yLkS5OlYyKM7:TR?=	NYS5UoRVW0GQR1XS
HC-1	NHTkNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7Cb5VIUUN3ME2wMlUxPDd\|IN88US=>	NEPFWodUSU6JRWK=
ACN	NW\GN3c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXsS41KSzVyPUCuOVExOjhizszN	MVrTRW5ITVJ?
HCC1599	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwNUG1O{DPxE1?	MmLKV2FPT0WU
MV-4-11	M1HST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwNUOwOFEh\|ryP	MWDTRW5ITVJ?
LC-2-ad	NYPCU\|lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PWfGlEPTB;MD61N\|Y3OyEQvF2=	NWTFUVZ[W0GQR1XS
HL-60	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwNUSyOlEh\|ryP	NIfTV4ZUSU6JRWK=
NB17	M1L5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWO2Rmc6UUN3ME2wMlU1OzhizszN	MnH4V2FPT0WU
TE-1	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULtT2NCUUN3ME2wMlU2OzB4IN88US=>	MXPTRW5ITVJ?
NCI-H524	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHLcIZOUUN3ME2wMlU2PDBzIN88US=>	MoPCV2FPT0WU
MZ7-mel	NYfJXoZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDlTnlKSzVyPUCuOVYyODVizszN	NWr1Wm94W0GQR1XS
L-363	NUHpZXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPIWFVKSzVyPUCuOVY3PTdizszN	M1rCeHNCVkeHUh?=
BL-41	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwNU[4PFkh\|ryP	NFvhRYhUSU6JRWK=
LU-134-A	NWfNWoVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\5XZVKSzVyPUCuOVcxPzNizszN	MVXTRW5ITVJ?
SIG-M5	NWDZcXVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;UTWM2OD1yLkW3PFQ5KM7:TR?=	NGnkZXpUSU6JRWK=
ONS-76	NEDKZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mme3TWM2OD1yLkW4NlQzKM7:TR?=	NUfWZolFW0GQR1XS
KARPAS-299	NWjLepM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTOXpBsUUN3ME2wMlU5PTB2IN88US=>	MVfTRW5ITVJ?
DU-4475	NGjqNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\aWXpUUUN3ME2wMlU5PzB\|IN88US=>	NITMbXNUSU6JRWK=
NB69	NIDjSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HETGlEPTB;MD61PVgzPSEQvF2=	MWnTRW5ITVJ?
MHH-PREB-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwNkC3NVkh\|ryP	Mne1V2FPT0WU
LU-165	NFfyWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlP1TWM2OD1yLk[xPFEzKM7:TR?=	MUnTRW5ITVJ?
LOUCY	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLrTWM2OD1yLk[zN\|Y1KM7:TR?=	MmHmV2FPT0WU
NCI-H526	NHHa[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHafHVKSzVyPUCuOlM2PDFizszN	NVH0N3NuW0GQR1XS
KE-37	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUL0dXA5UUN3ME2wMlY1Ojd4IN88US=>	NIrHVGdUSU6JRWK=
NALM-6	M1XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13QNGlEPTB;MD62OFg3KM7:TR?=	MWPTRW5ITVJ?
CW-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGruepJKSzVyPUCuOlU4QTRizszN	NIP2WW5USU6JRWK=
SU-DHL-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fFUmlEPTB;MD62OVk1PyEQvF2=	M3rESXNCVkeHUh?=
NB13	M4W5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrRRmxRUUN3ME2wMlY3QDF5IN88US=>	NITtcpJUSU6JRWK=
QIMR-WIL	NFnVTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwNkizOFMh\|ryP	NFjKOWNUSU6JRWK=
ECC12	NWrhV45ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvJfIdKSzVyPUCuO\|AxQDZizszN	NF25XZNUSU6JRWK=
KALS-1	NVn0T4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzjTWM2OD1yLkewOFkzKM7:TR?=	NGrnO\|BUSU6JRWK=
COR-L279	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7KPFl[UUN3ME2wMlcxQTl4IN88US=>	MkSzV2FPT0WU
NB14	NYW2U\|hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwN{K2NVch\|ryP	M2PNd3NCVkeHUh?=
CCRF-CEM	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwN{S2OlEh\|ryP	NVu5OFNqW0GQR1XS
SW954	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwN{W5PVkh\|ryP	MYLTRW5ITVJ?
IST-SL1	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF[0SplKSzVyPUCuO\|c{PDhizszN	NIHrSnhUSU6JRWK=
LAMA-84	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv4dWdKSzVyPUCuO\|c2PjdizszN	M3;2d3NCVkeHUh?=
Daudi	NV3wb49FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\TcWlEPTB;MD63O\|Y5OSEQvF2=	NF;sVnpUSU6JRWK=
BC-3	NHnETodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPHT5pKSzVyPUCuO\|g{ODhizszN	MUTTRW5ITVJ?
HCC2998	M3XBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwN{izOkDPxE1?	MWXTRW5ITVJ?
NCI-H69	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfzb5hUUUN3ME2wMlgxOTR5IN88US=>	M1i0b3NCVkeHUh?=
CPC-N	M{O5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;FWGxKSzVyPUCuPFA2OjRizszN	NFr0PVJUSU6JRWK=
NOMO-1	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwOEGwPFQh\|ryP	M{f0cXNCVkeHUh?=
CESS	M3XDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwOEGxPVch\|ryP	MYTTRW5ITVJ?
LC4-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\wd2FKSzVyPUCuPFQxODdizszN	M1fwenNCVkeHUh?=
BL-70	M1LwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwOEW3NFIh\|ryP	NGjHXIxUSU6JRWK=
ES4	NYC4R5R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPYTJNKSzVyPUCuPFU5PjhizszN	NYjZbnF[W0GQR1XS
HCE-T	NEHIOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVj2W5J4UUN3ME2wMlg4OTdzIN88US=>	NV;jOGx5W0GQR1XS
JAR	NV3uW45vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4foW2lEPTB;MD64O\|gzPyEQvF2=	MoOzV2FPT0WU
ST486	NUL1ToxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwOEe5NVch\|ryP	M3PxfnNCVkeHUh?=
KS-1	NFHCUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvHTWM2OD1yLki4NFk3KM7:TR?=	M1\ROXNCVkeHUh?=
GDM-1	NHv4NVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G5NmlEPTB;MD64PFY5PyEQvF2=	NILlRpNUSU6JRWK=
EHEB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnSTWM2OD1yLkmyOVg2KM7:TR?=	Mki1V2FPT0WU
LB2518-MEL	NWjmT2x3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;zS25KSzVyPUCuPVMzQDRizszN	NIrhUYtUSU6JRWK=
GOTO	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mof4TWM2OD1yLkm1NFc3KM7:TR?=	M3PqNnNCVkeHUh?=
LXF-289	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwOUW5NFEh\|ryP	NYnm[GJqW0GQR1XS
ES6	NIH2O5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoO3TWM2OD1yLkm2OFM4KM7:TR?=	M3v1U3NCVkeHUh?=
OS-RC-2	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmO4TWM2OD1yLkm2PFMh\|ryP	MlTxV2FPT0WU
DMS-153	NYmzTYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;0fZlGUUN3ME2wMlk4PDZ7IN88US=>	MkC0V2FPT0WU
SK-PN-DW	NHfMVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwOUe4N\|Eh\|ryP	MXfTRW5ITVJ?
HH	NUjPW4E4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLSXIhKSzVyPUCuPVg6PTlizszN	MX7TRW5ITVJ?
SH-4	NIW1bYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHJdllKUUN3ME2xMlAzPDFizszN	NV\teHI2W0GQR1XS
MOLT-4	NV7M[lJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3C[3hKSzVyPUGuNFM1PTRizszN	NI\xV4hUSU6JRWK=
TGW	NF;lO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPHTWM2OD1zLkC3Olc2KM7:TR?=	MXvTRW5ITVJ?
L-540	M{nZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnMPJh1UUN3ME2xMlExPjB2IN88US=>	MXHTRW5ITVJ?
PF-382	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mme1TWM2OD1zLkGxOVE{KM7:TR?=	NXS1OlV4W0GQR1XS
LC-1F	NYOycpJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTITYtCUUN3ME2xMlEzODB5IN88US=>	NF7LW2xUSU6JRWK=
OVCAR-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2foVmlEPTB;MT6xN\|E3PSEQvF2=	NFTYUHZUSU6JRWK=
A4-Fuk	NVrBS\|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PIW2lEPTB;MT6xOVM3PCEQvF2=	M{DKbHNCVkeHUh?=
HCC2218	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTFwMU[2OFEh\|ryP	NYDsT3FvW0GQR1XS
HAL-01	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVy5bXFrUUN3ME2xMlE3QTR\|IN88US=>	NGPBXlRUSU6JRWK=
IST-MEL1	NEXSc\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\hT2lEPTB;MT6xO\|Y2QSEQvF2=	NELiSVBUSU6JRWK=
NCI-H719	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrETGl5UUN3ME2xMlE4QDl6IN88US=>	M3PWU3NCVkeHUh?=
EVSA-T	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTFwMUixNVQh\|ryP	M2\qZnNCVkeHUh?=
SK-NEP-1	NWPERnhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXZeWNKSzVyPUGuNlAzPjZizszN	NHfHR3ZUSU6JRWK=
OCUB-M	M2q0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\wcoVKSzVyPUGuNlE1QDlizszN	MX3TRW5ITVJ?
MEG-01	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkC2TWM2OD1zLkKyNVE5KM7:TR?=	MknhV2FPT0WU
no-10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGS5bnlKSzVyPUGuNlMyOTJizszN	NFPjSGlUSU6JRWK=
MHH-CALL-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\lNWpRUUN3ME2xMlI1PzJzIN88US=>	NUHKOJNRW0GQR1XS
SK-N-DZ	M135PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TNZ2lEPTB;MT6yOFc4PiEQvF2=	MnTQV2FPT0WU
SCLC-21H	M{TjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHXTWM2OD1zLkK2OFc5KM7:TR?=	M{n0XXNCVkeHUh?=
CTV-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33rOGlEPTB;MT6yO\|QzPSEQvF2=	NVjrSGNOW0GQR1XS
NB1	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrZTWM2OD1zLkK3O\|MzKM7:TR?=	NIHMWnZUSU6JRWK=
NCI-H64	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\MZYwxUUN3ME2xMlI5PDZ{IN88US=>	M3\OdHNCVkeHUh?=
MDA-MB-134-VI	M1:2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHFR3lGUUN3ME2xMlI5PTd5IN88US=>	MYHTRW5ITVJ?
LB2241-RCC	NEDme21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTFwMki2OlMh\|ryP	MnjvV2FPT0WU
8-MG-BA	NFPucZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTFwMki4OlYh\|ryP	MXrTRW5ITVJ?
LP-1	NFi4coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnmTWM2OD1zLkK5PVQ4KM7:TR?=	Ml3jV2FPT0WU
LS-411N	NWLoNmdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjNWYtKSzVyPUGuN\|A6QThizszN	M{DvV3NCVkeHUh?=
CAL-148	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;2W5JKSzVyPUGuN\|I2PDJizszN	Mo\RV2FPT0WU
NCI-H2171	M4W2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXrcYFKSzVyPUGuN\|Q2ODJizszN	MmS1V2FPT0WU
JiyoyeP-2003	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\GPVNKSzVyPUGuN\|U{QSEQvF2=	Mo[4V2FPT0WU
NCI-H2107	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTFwM{W4PFMh\|ryP	NV\DcohEW0GQR1XS
BB30-HNC	NIPjVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrCV5VKSzVyPUGuN\|g6PzhizszN	M4jMcnNCVkeHUh?=
K-562	NYLUZZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorwTWM2OD1zLkO5NlE6KM7:TR?=	NVnnSWZEW0GQR1XS
PSN1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfncGJKSzVyPUGuOFIzQDdizszN	MknFV2FPT0WU
HCC2157	NX75fWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnETWM2OD1zLkSyOlkyKM7:TR?=	MkfuV2FPT0WU
SBC-1	M{fnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLVTWM2OD1zLkSyO\|QyKM7:TR?=	MojXV2FPT0WU
MC116	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwNEO2NVUh\|ryP	NVzIOod{W0GQR1XS
KARPAS-422	M1jQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrOSohPUUN3ME2xMlQ2OzV6IN88US=>	M{PhW3NCVkeHUh?=
LB996-RCC	NIfLXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrTU\|QyUUN3ME2xMlQ4OTB\|IN88US=>	MUfTRW5ITVJ?
MSTO-211H	MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTFwNEe5PFch\|ryP	Ml[yV2FPT0WU
BT-474	NVPnU4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjvVHBWUUN3ME2xMlUyPzZ2IN88US=>	NVHHNXNGW0GQR1XS
A388	NV;0bWdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofRTWM2OD1zLkWxPVQ2KM7:TR?=	NYDvdXNPW0GQR1XS
SJSA-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fHTmlEPTB;MT61NlI3KM7:TR?=	NF;lU3JUSU6JRWK=
COLO-829	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fwTmlEPTB;MT61N\|U3PCEQvF2=	Ml\PV2FPT0WU
KM-H2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFwNU[2O{DPxE1?	MUXTRW5ITVJ?
GR-ST	NWXudZNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXCZnVKSzVyPUGuOVY5OiEQvF2=	NHTSdmtUSU6JRWK=
RPMI-8866	NX3PdGkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fBZ2lEPTB;MT62NFE1PCEQvF2=	MUfTRW5ITVJ?
KG-1	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWL0TmQyUUN3ME2xMlYyQTBzIN88US=>	MlfUV2FPT0WU
NCI-H82	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv3WFNKSzVyPUGuOlM1ODZizszN	NYDoUItyW0GQR1XS
LB1047-RCC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PyTmlEPTB;MT62N\|Q2QSEQvF2=	MUnTRW5ITVJ?
KM12	NWjVU2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{OySmlEPTB;MT62OFch\|ryP	MXrTRW5ITVJ?
NB5	NImyXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nzcmlEPTB;MT62OVY4PyEQvF2=	MWrTRW5ITVJ?
HDLM-2	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTFwNkiyPFEh\|ryP	MXrTRW5ITVJ?
KU812	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTFwNkm2NFUh\|ryP	M{jOd3NCVkeHUh?=
DB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\OR5BKSzVyPUGuO\|A{PTNizszN	MnS0V2FPT0WU
HD-MY-Z	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nVO2lEPTB;MT63OVI{PCEQvF2=	MWrTRW5ITVJ?
KURAMOCHI	MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTFwN{eyNFch\|ryP	NFjIfodUSU6JRWK=
ETK-1	M4PRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHwOlNKSzVyPUGuO\|g5PzlizszN	NYrHZ2lGW0GQR1XS
SK-UT-1	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXPS2dKSzVyPUGuO\|k{QDhizszN	MWnTRW5ITVJ?
HUTU-80	NGX5TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HjN2lEPTB;MT63PVUxQCEQvF2=	NUi2eG9FW0GQR1XS
ES7	NEXmZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYf3emZKUUN3ME2xMlgxOzB{IN88US=>	NFjSTItUSU6JRWK=
SW872	M1fw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnETWM2OD1zLkixN\|k2KM7:TR?=	MV3TRW5ITVJ?
TK10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETobXBKSzVyPUGuPFMyODhizszN	M4rpPHNCVkeHUh?=
LB831-BLC	M3fkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrkTWM2OD1zLkizOVY{KM7:TR?=	MmTMV2FPT0WU
TE-9	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nFWGlEPTB;MT64OFQzOiEQvF2=	NEXRUWFUSU6JRWK=
MLMA	NGf4[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTscYNoUUN3ME2xMlg5OjN2IN88US=>	NWPNbG9lW0GQR1XS
D-542MG	NVq5WFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHIUHpVUUN3ME2xMlg6Ozd\|IN88US=>	MXHTRW5ITVJ?
EW-16	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7mRY9KSzVyPUGuPVI4OiEQvF2=	MXzTRW5ITVJ?
LOXIMVI	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTFwOUOyPEDPxE1?	NYjxe4dLW0GQR1XS
GB-1	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTFwOUO4OlYh\|ryP	NFf5cY5USU6JRWK=
IST-SL2	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPXXlVDUUN3ME2yMlAxOjZ{IN88US=>	NHLYeFRUSU6JRWK=
LAN-6	NX7jflRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj2elJKSzVyPUKuNFE6PjZizszN	NV7yTYxFW0GQR1XS
NCI-H510A	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDMcGtKSzVyPUKuNFQ2ODJizszN	NYrJTZFsW0GQR1XS
NCI-H1092	MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nKPWlEPTB;Mj6wOVEzPCEQvF2=	M4[0VXNCVkeHUh?=
HT	NEWyVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTJwMUC0OVQh\|ryP	MYDTRW5ITVJ?
RL95-2	M4S3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfjTWM2OD1{LkGxOFgzKM7:TR?=	NE\B[2hUSU6JRWK=
NCI-H1355	M{K1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LaXmlEPTB;Mj6xNVc6OiEQvF2=	MUPTRW5ITVJ?
NCI-H720	NXrHUmllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnrV29KSzVyPUKuNVY5PzNizszN	MWPTRW5ITVJ?
NCI-H1522	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X0TmlEPTB;Mj6yNVczOyEQvF2=	NWPacoUyW0GQR1XS
LB373-MEL-D	NEf0fodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XJWGlEPTB;Mj6yOlkxOiEQvF2=	MlO0V2FPT0WU
DG-75	NHvsd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoThTWM2OD1{LkK3NVQ5KM7:TR?=	MnXDV2FPT0WU
ML-2	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTJwM{K4OVUh\|ryP	MmTGV2FPT0WU
SF126	M4XWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTJwM{OwPVQh\|ryP	Mn7pV2FPT0WU
MPP-89	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTJwM{OxOFUh\|ryP	MlXUV2FPT0WU
NCI-H345	M3rQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzVNWpIUUN3ME2yMlM{Ojd5IN88US=>	M3u2NnNCVkeHUh?=
LS-123	NYm4R5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Tt[2lEPTB;Mj6zOFk{PiEQvF2=	NIDyZoZUSU6JRWK=
NB10	NHvpTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDwTWM2OD1{LkSxNFkzKM7:TR?=	NUK5Z4ZjW0GQR1XS
CGTH-W-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\LS4czUUN3ME2yMlQzOjZ5IN88US=>	MUPTRW5ITVJ?
CP66-MEL	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjHelU4UUN3ME2yMlQ4PzdizszN	NWXlUoNmW0GQR1XS
L-428	NUS0N29yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTJwNEi1NlEh\|ryP	NIDrZ5hUSU6JRWK=
DMS-79	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknHTWM2OD1{LkW0NVA{KM7:TR?=	M1HpXXNCVkeHUh?=
NCI-H1882	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPkRoNlUUN3ME2yMlY4PTZ{IN88US=>	MlH2V2FPT0WU
KGN	NWXHOZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTJwN{[4O\|Yh\|ryP	NVzFc4Q1W0GQR1XS
EW-1	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUO1U2h1UUN3ME2yMlc4ODh\|IN88US=>	MoH4V2FPT0WU
U-266	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTKTWM2OD1{Lki0PFI{KM7:TR?=	NF3p[I5USU6JRWK=
COLO-320-HSR	M2P6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJwOEW2OFEh\|ryP	NXX1S4ZCW0GQR1XS
KMOE-2	NUHNOlhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DXN2lEPTB;Mj64O\|cyOSEQvF2=	M{f3XHNCVkeHUh?=
BB49-HNC	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTJwOUK0PEDPxE1?	NITGNZZUSU6JRWK=
GI-1	NELsfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLnTWM2OD1{LkmyPVU4KM7:TR?=	MWPTRW5ITVJ?
NCI-H1304	M1;HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkX5TWM2OD1\|LkCwOVEyKM7:TR?=	M1TL[3NCVkeHUh?=
NCI-H2227	NHPOSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTNwMEKwO\|kh\|ryP	MXrTRW5ITVJ?
U-87-MG	NEDVV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnrTWM2OD1\|LkCzOVE{KM7:TR?=	M{XFUnNCVkeHUh?=
NCI-H747	Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mom5TWM2OD1\|LkC1NlA3KM7:TR?=	MY\TRW5ITVJ?
CTB-1	NXH6RWkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETJT3RKSzVyPUOuNFU{PzZizszN	Moe5V2FPT0WU
RPMI-8226	NIPL[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnue2t{UUN3ME2zMlE1Ozd6IN88US=>	NEfORnRUSU6JRWK=
NCI-H2141	NHq4Sm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33FVGlEPTB;Mz6xOlU3PiEQvF2=	M125NnNCVkeHUh?=
IST-MES1	NUC2Sm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlqwTWM2OD1\|LkG4Nlc6KM7:TR?=	M2nnPXNCVkeHUh?=
TE-5	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj3bI1KSzVyPUOuNlE{PDJizszN	M2TCRXNCVkeHUh?=
UACC-257	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2K3cmlEPTB;Mz60N\|Y2QSEQvF2=	MXTTRW5ITVJ?
SK-N-FI	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjHdFlKSzVyPUOuOFUzOjdizszN	NIW1UYlUSU6JRWK=
MFH-ino	NFyx[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HrfmlEPTB;Mz60OlU5QSEQvF2=	NHraTm5USU6JRWK=
SF268	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHFWWIzUUN3ME2zMlQ5OTd2IN88US=>	MX3TRW5ITVJ?
TE-12	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnv5TWM2OD1\|LkWxOlk6KM7:TR?=	NWjRUWdVW0GQR1XS
NB6	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTnTWM2OD1\|LkW1OVY{KM7:TR?=	M16y[HNCVkeHUh?=
DJM-1	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPwNJlKSzVyPUOuOVk5QTlizszN	NVzpNYhJW0GQR1XS
MZ1-PC	M3vGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP5UotKSzVyPUOuOlE3OjRizszN	M{DycXNCVkeHUh?=
OCI-AML2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzibmxKSzVyPUOuOlI3PzFizszN	NIrFZ\|BUSU6JRWK=
NCI-H1155	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnwNIdKSzVyPUOuO\|A6PDdizszN	MXnTRW5ITVJ?
RKO	NVrmUmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPLXXVpUUN3ME2zMlc4OTh7IN88US=>	NI\2OmpUSU6JRWK=
ECC4	M1PnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TZZWlEPTB;Mz65O\|E6PSEQvF2=	MlHuV2FPT0WU
BB65-RCC	NXjyeGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXITWM2OD1\|Lkm3OVQ4KM7:TR?=	MlSxV2FPT0WU
EB-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjUTWM2OD1\|Lkm5OlM{KM7:TR?=	NUezb\|VqW0GQR1XS
SHP-77	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;ZNnV3UUN3ME20MlAxPTJ2IN88US=>	M3G0W3NCVkeHUh?=
NCI-H2196	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj1SFNTUUN3ME20MlA2PjJ3IN88US=>	M3vWXXNCVkeHUh?=
GI-ME-N	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfN[ldOUUN3ME20MlA3Ozl7IN88US=>	M{PLfnNCVkeHUh?=
MN-60	M4DTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7mVZZ3UUN3ME20MlExQDdizszN	NV7oNYtyW0GQR1XS
NCI-H1694	M4DGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4H1dGlEPTB;ND6xN\|QxPSEQvF2=	M3:yUXNCVkeHUh?=
LU-65	NEjYOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PqUmlEPTB;ND6xOVM{OiEQvF2=	Ml3YV2FPT0WU
NCI-H1436	MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTRwMUizN\|Mh\|ryP	M1HFbHNCVkeHUh?=
KINGS-1	M3;uPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTRwM{G0N\|Ih\|ryP	NYHwc4hHW0GQR1XS
GT3TKB	NGrIXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HqO2lEPTB;ND6zN\|I3QCEQvF2=	M{HXO3NCVkeHUh?=
Becker	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPYTYxKSzVyPUSuN\|c{OTJizszN	MkL4V2FPT0WU
HCC1187	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPJVFB3UUN3ME20Mlg6PjV5IN88US=>	MYrTRW5ITVJ?
D-502MG	NH;aTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXtbpJQUUN3ME21MlAxPDF4IN88US=>	NH2yPWlUSU6JRWK=
VA-ES-BJ	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjSTWM2OD13LkGzO\|c5KM7:TR?=	Mni2V2FPT0WU
NB7	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M132ZWlEPTB;NT6xOFEyOiEQvF2=	NX7PSpRpW0GQR1XS
SW962	NXvY[nVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LoNmlEPTB;NT6zPFgyPCEQvF2=	MkDiV2FPT0WU
no-11	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDKdpNKSzVyPUWuO\|Y{PDNizszN	NHX5co1USU6JRWK=
KNS-81-FD	NIDPVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfQdGppUUN3ME21MlkxPjl2IN88US=>	MVzTRW5ITVJ?
COLO-684	M4jxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvJTWM2OD13Lkm5OFk1KM7:TR?=	MnS5V2FPT0WU
D-263MG	M4nVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUe3TVdZUUN3ME22MlA5QDl3IN88US=>	NWj3d\|liW0GQR1XS
EW-24	M{PteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnpfWhMUUN3ME22MlI5PTFizszN	Ml\QV2FPT0WU
TE-10	NV;0PFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;5XZIyUUN3ME22MlQzPjJ\|IN88US=>	MoXyV2FPT0WU
EKVX	M1W4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TiNWlEPTB;Nj60OlMzOSEQvF2=	NYHpdZZmW0GQR1XS
NCI-H1648	M2DwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moe4TWM2OD14Lk[3OVU4KM7:TR?=	Mli3V2FPT0WU
LB771-HNC	NILGUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3nTWM2OD14LkmyN\|AyKM7:TR?=	NFjwfpVUSU6JRWK=
SK-MEL-1	M3jMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRThwMUOxOlYh\|ryP	NIHkVHBUSU6JRWK=
COLO-668	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRThwMke3PFYh\|ryP	MWTTRW5ITVJ?
EW-12	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRThwNEC4NFMh\|ryP	NH71cYRUSU6JRWK=
A253	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRThwOES2OlEh\|ryP	NV20fmRWW0GQR1XS
NCI-H2126	MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRThwOEmzNVkh\|ryP	NEXnc4lUSU6JRWK=
Calu-6	M2nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPFVHdKSzVyPUiuPVkxPDJizszN	MWHTRW5ITVJ?
NCI-H23	NWrndo1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoL2TWM2OD17LkG3O\|Q3KM7:TR?=	MkjzV2FPT0WU
WSU-NHL	M3\Hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfZRZI2UUN3ME25Mlc4PDd6IN88US=>	M2XCU3NCVkeHUh?=
MMAC-SF	NELrZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTlwOUe5NFQh\|ryP	NVq5fZlLW0GQR1XS
SK-LMS-1	NXjIToFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFyLkK4N\|Qh\|ryP	MV3TRW5ITVJ?
GCIY	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP0WY5KSzVyPUGwMlU6OjRizszN	MXHTRW5ITVJ?
TE-15	M1vISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fsV2lEPTB;MUGuOlAxPCEQvF2=	MmrMV2FPT0WU
EoL-1-cell	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HnR2lEPTB;MUGuO\|Y5OiEQvF2=	MXfTRW5ITVJ?
NCI-H2081	NGjmW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnqVGVKSzVyPUGxMlc4QDZizszN	NXfHbYI3W0GQR1XS
EW-3	M1\qbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7xTWM2OD1zMj6yOFY{KM7:TR?=	MWrTRW5ITVJ?
CAS-1	M1yxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTF{LkO2N\|Eh\|ryP	MWTTRW5ITVJ?
C2BBe1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1O0[WlEPTB;MUKuOlE{OSEQvF2=	M2izWXNCVkeHUh?=
D-247MG	NFuyO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\tWINPUUN3ME2xNk44QTV{IN88US=>	MXXTRW5ITVJ?
NCI-SNU-5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LmfGlEPTB;MUKuPFAyOyEQvF2=	MnPqV2FPT0WU
LS-1034	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NES1dWdKSzVyPUG0MlM6PzVizszN	M4X4ZnNCVkeHUh?=
EW-18	NYjt[2NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Kzb2lEPTB;MUSuOFQ5KM7:TR?=	MnHzV2FPT0WU
Raji	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrTdmx{UUN3ME2xOE42ODR7IN88US=>	MXfTRW5ITVJ?
D-283MED	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHL0OFNKSzVyPUG0MlYzPzFizszN	NFv4PVVUSU6JRWK=
MZ2-MEL	M3\JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTF2Lkm2PVYh\|ryP	MWLTRW5ITVJ?
NCI-SNU-16	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTYWZZEUUN3ME2xOU41PjN\|IN88US=>	MkWyV2FPT0WU
P30-OHK	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnNZ5hKSzVyPUG3Mlc5OzFizszN	MlfxV2FPT0WU
RXF393	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWX5RpRMUUN3ME2xPU4xOTh4IN88US=>	M2XEZ3NCVkeHUh?=
NCI-H1395	MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzwT3lCUUN3ME2yNE43PzB\|IN88US=>	NUDPbIExW0GQR1XS
U-698-M	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\4SY1jUUN3ME2yNE44ODd3IN88US=>	NVTw[W16W0GQR1XS
NCI-SNU-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTJyLkeyNlMh\|ryP	MXzTRW5ITVJ?
SW684	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnVNppKSzVyPUKxMlE4OTZizszN	MX3TRW5ITVJ?
NCI-H716	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTJzLkOxOVQh\|ryP	NEGwVGFUSU6JRWK=
JVM-2	M3;QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHVU21PUUN3ME2yNU41OTN\|IN88US=>	NVLUd5psW0GQR1XS
NCI-H1581	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DqN2lEPTB;MkKuOFE1QCEQvF2=	M322[XNCVkeHUh?=
CA46	M{fXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfScHl4UUN3ME2zNU43QTN4IN88US=>	MkDaV2FPT0WU
SNB75	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfGdJFqUUN3ME2zN{43PTB\|IN88US=>	NGL5OllUSU6JRWK=
KNS-42	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHO5eoNKSzVyPUO1Mlk3OjRizszN	MlXvV2FPT0WU
TUR	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHHcJdnUUN3ME2zOk4xPTJzIN88US=>	NWewfVdXW0GQR1XS
REH	M1TuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHnSnNKSzVyPUO3MlgzOTFizszN	M1LHVHNCVkeHUh?=
EW-22	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPRTWM2OD12Mj6yPFg2KM7:TR?=	MUDTRW5ITVJ?
NCI-H446	NYTLSI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHzfYczUUN3ME20Nk44QDV\|IN88US=>	M4\EN3NCVkeHUh?=
ES3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXjNWdKSzVyPUSzMlE{OzlizszN	MX7TRW5ITVJ?
EW-11	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jjeGlEPTB;NESuPFIyQCEQvF2=	MWnTRW5ITVJ?
RH-1	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnv3TWM2OD12Nz61PFEzKM7:TR?=	NFrwOmRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80 Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SNDX-275

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Vorinostat (SAHA, MK0683)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)

Cited by 117 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Entinostat (MS-275) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)

Cited by 117 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Entinostat (MS-275) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)